SCHEMBL10028358

SCHEMBL10028358

CC(C)C1CC[C@@H](C)C[C@H]1OC(=O)CCl

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 2/20 0.59
EPHX1 P07099 3/20 0.55
ALDH1A1 P00352 8/20 0.52
NPSR1 Q6W5P4 4/20 0.51
TSHR P16473 2/20 0.51
MAPT P10636 2/20 0.51
LMNA P02545 2/20 0.51
USP2 O75604 1/20 0.51
KMT2A Q03164 3/20 0.50
HPGD P15428 2/20 0.50
MEN1 O00255 2/20 0.50
MAPK1 P28482 4/20 0.49
KDM4E B2RXH2 1/20 0.49
GAA P10253 1/20 0.49
MITF O75030 2/20 0.46
HTT P42858 2/20 0.46
NPC1 O15118 1/20 0.46
TP53 P04637 1/20 0.46
RAB9A P51151 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10062430 1.00 CYP19A1 (0.59) CYP19A1EPHX1ALDH1A1NPSR1TSHR
SCHEMBL14032266 1.00 CYP19A1 (0.59) CYP19A1EPHX1ALDH1A1NPSR1TSHR
SCHEMBL12191998 1.00 CYP19A1 (0.59) CYP19A1EPHX1ALDH1A1NPSR1TSHR
SCHEMBL474094 1.00 CYP19A1 (0.59) CYP19A1EPHX1ALDH1A1NPSR1TSHR
SCHEMBL23255563 0.87 CYP19A1 (0.61) CYP19A1EPHX1ALDH1A1NPSR1TSHR
SCHEMBL1665360 0.87 CYP19A1 (0.61) CYP19A1EPHX1ALDH1A1NPSR1TSHR
SCHEMBL3424391 0.87 CYP19A1 (0.61) CYP19A1EPHX1ALDH1A1NPSR1TSHR
SCHEMBL21610695 0.87 CYP19A1 (0.61) CYP19A1EPHX1ALDH1A1NPSR1TSHR
SCHEMBL7991614 0.87 CYP19A1 (0.61) CYP19A1EPHX1ALDH1A1NPSR1TSHR
SCHEMBL7991612 0.87 CYP19A1 (0.61) CYP19A1EPHX1ALDH1A1NPSR1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2058300-B1 SUCCINIC ACID DIESTER DERIVATIVE, PROCESS FOR PRODUCTION THEREOF, AND USE OF THE DERIVATIVE IN THE PRODUCTION OF PHARMACEUTICAL PREPARATION DAINIPPON SUMITOMO PHARMA CO (JP) 2013-01-09 EP disclosed
US-8106230-B2 Succinic acid diester derivative, process for production thereof, and use of the derivative in the production of pharmaceutical preparation DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-01-31 US disclosed
US-8030486-B2 Succinic acid diester derivative, process for production thereof, and use of the derivative in the production of pharmaceutical preparation DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-10-04 US disclosed
US-20110046373-A1 SUCCINIC ACID DIESTER DERIVATIVE, PROCESS FOR PRODUCTION THEREOF, AND USE OF THE DERIVATIVE IN THE PRODUCTION OF PHARMACEUTICAL PREPARATION INAGAKI TAKASHI 2011-02-24 US disclosed
US-20100076203-A1 Succinic acid diester derivative, process for production thereof, and use of the derivative in the production of pharmaceutical preparation DAINIPPON SUMITOMO PHARMA CO., LTD. 2010-03-25 US disclosed
EP-2058300-A1 SUCCINIC ACID DIESTER DERIVATIVE, PROCESS FOR PRODUCTION THEREOF, AND USE OF THE DERIVATIVE IN THE PRODUCTION OF PHARMACEUTICAL PREPARATION Dainippon Sumitomo Pharma Co., Ltd. (JP) 2009-05-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046373-A1 SUCCINIC ACID DIESTER DERIVATIVE, PROCESS FOR PRODUCTION THEREOF, AND USE OF THE DERIVATIVE IN THE PRODUCTION OF PHARMACEUTICAL PREPARATION SUCNR1, DLST, SHMT2 CYP19A1 533/4885EPHX1 3382/4885ALDH1A1 486/4885
US-20100076203-A1 Succinic acid diester derivative, process for production thereof, and use of the derivative in the production of pharmaceutical preparation SUCNR1, DLST, SHMT2 CYP19A1 533/4885EPHX1 3382/4885ALDH1A1 486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.